Curative Biotechnology, Inc.

Curative Biotechnology, Inc. is a biopharmaceutical company that identifies, in-licenses, and develops therapeutic drug candidates for rare disease indications. The company develops Metformin Reformulation for intermediate dry macular degeneration and geographic atrophy. It also develops IMT504, a novel immunotherapy for late-stage rabies, and CUBT906, a fully humanized CD56 monoclonal antibody that carries a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration. Curative Biotechnology, Inc. has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 for late-stage rabies and as a COVID-19 vaccine. The company was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.